Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.76 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.71 |
| ▸ | FLT1 | P17948 | 1/20 | 0.71 |
| ▸ | CDK4 | P11802 | 8/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.67 |
| ▸ | CCND1 | P24385 | 8/20 | 0.67 |
| ▸ | CDK2 | P24941 | 8/20 | 0.67 |
| ▸ | CCND3 | P30281 | 8/20 | 0.67 |
| ▸ | JAK2 | O60674 | 5/20 | 0.66 |
| ▸ | JAK1 | P23458 | 5/20 | 0.66 |
| ▸ | TYK2 | P29597 | 5/20 | 0.66 |
| ▸ | JAK3 | P52333 | 5/20 | 0.66 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.63 |
| ▸ | KDR | P35968 | 3/20 | 0.63 |
| ▸ | CDK1 | P06493 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5513046 | 0.90 | CDK4 (0.67) | ITKPDPK1FGFR1FLT1CDK4 | |
| SCHEMBL3537487 | 0.89 | ITK (0.80) | ITKPDPK1FGFR1FLT1CDK4 | |
| SCHEMBL5510140 | 0.87 | CDK4 (0.83) | ITKPDPK1FGFR1FLT1CDK4 | |
| SCHEMBL3533024 | 0.84 | PDPK1 (0.73) | ITKPDPK1FGFR1FLT1CDK4 | |
| SCHEMBL29714859 | 0.84 | FGFR1 (1.00) | ITKPDPK1FGFR1FLT1CDK4 | |
| SCHEMBL311148 | 0.84 | FGFR1 (1.00) | ITKPDPK1FGFR1FLT1CDK4 | |
| SCHEMBL3531870 | 0.83 | PDPK1 (0.71) | ITKPDPK1FGFR1FLT1CDK4 | |
| SCHEMBL3534494 | 0.83 | PDPK1 (0.71) | ITKPDPK1FGFR1FLT1CDK4 | |
| SCHEMBL4989411 | 0.83 | PDPK1 (0.71) | ITKPDPK1FGFR1FLT1CDK4 | |
| SCHEMBL3533017 | 0.83 | PDPK1 (0.71) | ITKPDPK1FGFR1FLT1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | ITK 222/4885PDPK1 61/4885FGFR1 609/4885 |
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | ITK 1055/4885PDPK1 1862/4885FGFR1 886/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | ITK 266/4885PDPK1 94/4885FGFR1 725/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | ITK 855/4885PDPK1 1896/4885FGFR1 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.